Arrowhead Pharmaceuticals, Inc.
HealthcareNASDAQ:ARWR · NASDAQ Global Select
-$0.31 today
Vol 1.17M · Avg 1.89M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-0.3%
avg -66.9%
ROIC
4.6%
avg -36.2%
ROA
-0.1%
avg -30.6%
Analysis
ROIC is currently the strongest return metric at 4.6% versus its period average of -36.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Christopher R. Anzalone | Chairman, Chief Executive Officer & President | $2.22M | — | 57 | $3.80M | 2.70% |
Patrick O'Brien | COO & Secretary | $1.05M | — | 62 | $472,848.00 | 0.34% |
Daniel J. Apel | Chief Financial Officer | $1.04M | — | 60 | $162,905.00 | 0.12% |
James C. Hamilton | Chief Medical Officer and Head of R&D | $987,213.00 | — | 47 | $226,958.00 | 0.16% |
Bruce D. Given | Chief Medical Scientist | $486,308.00 | — | 72 | $62,514.00 | 0.04% |
Mark Davis | Founder and Founder & Director of Insert Therapeutics Inc & Calando | — | — | — | — | — |
Vincent Anzalone | Head of Investor Relations & Vice President | — | — | — | $3.80M | 2.70% |
Mark Seefeld | Head of Toxicology & Vice President | — | — | 72 | — | — |
Aaron Tan | Head of Tax | — | — | — | — | — |
Tao Pei | Chief Scientific Officer | — | — | — | — | — |
Howard Lovy | Director of Communications | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
67
$37.88M
Net Sentiment
$37.88M
Net selling
Most Active
Anzalone Christopher Richard
25 transactions
1–10 of 67
Analysis
Insiders reported 0 buys worth $0.00 and 67 sells worth $37.88M over the last 12 months. That adds up to net selling of $37.88M. Anzalone Christopher Richard was the most active insider with 25 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A7 analysts |
| Revenue | N/A | N/A | +37.5% | +74.3% (15yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at +37.5% over three years. Forward estimates point to Revenue at +74.3% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Axsome Therapeutics, Inc.
NASDAQ:AXSM
$13.19B
Krystal Biotech, Inc.
NASDAQ:KRYS
$9.41B
TG Therapeutics, Inc.
NASDAQ:TGTX
$7.64B
Alkermes plc
NASDAQ:ALKS
$7.43B
Metsera, Inc.
MTSR
$7.43B
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.08B
Vaxcyte, Inc.
NASDAQ:PCVX
$6.91B
Arcellx, Inc.
ACLX
$6.73B
PTC Therapeutics, Inc.
NASDAQ:PTCT
$6.22B
CRISPR Therapeutics AG
NASDAQ:CRSP
$4.82B
Who manages ARWR?
Arrowhead Pharmaceuticals, Inc. (ARWR) lists 11 active executives. The top listed executive is Mark Davis, Founder and Founder & Director of Insert Therapeutics Inc & Calando.
Are ARWR insiders buying or selling?
Recent insider activity shows net selling of $52.68M.
Explore More
Continue the stock analysis
Jump to another research area for this company.